Artemether–lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania

Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in many countries. This report describes a treatment failure despite adequate drug concentrations in a traveller returning from sub-Saharan Africa. Genotyping confirmed recrudescence and suggested reduced sensit...

Descripción completa

Detalles Bibliográficos
Autores principales: Färnert, Anna, Ursing, Johan, Tolfvenstam, Thomas, Rono, Josea, Karlsson, Lillemor, Sparrelid, Elda, Lindegårdh, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3416680/
https://www.ncbi.nlm.nih.gov/pubmed/22632033
http://dx.doi.org/10.1186/1475-2875-11-176
Descripción
Sumario:Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in many countries. This report describes a treatment failure despite adequate drug concentrations in a traveller returning from sub-Saharan Africa. Genotyping confirmed recrudescence and suggested reduced sensitivity. Potential sub-optimal effect of artemether-lumefantrine highlights the need to follow non-immune individuals the weeks after treatment.

Ejemplares similares